Generated: May 26, 2017
|Title:||Methods for the treatment of allergic rhinitis|
|Abstract:||Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.|
|Inventor(s):||Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA)|
|Assignee:||Sepracor Inc. (Marlborough, MA)|
1. A method of treating allergic rhinitis in a human comprising orally administering to a human a therapeutically effective amount of descarboethoxyloratadine, or a
pharmaceutically acceptable salt thereof, wherein the amount of the descarboethoxyloratadine administered is 0.1 mg to 5 mg per day.
2. The method of claim 1, wherein the amount of said descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, is administered together with a pharmaceutically acceptable carrier.